APAnton PozniakMD, FRCPSlidesetHIVGlobal HIV Clinical Forum 2017Optimizing Clinical Utility of Integrase Inhibitors- Anton Pozniak, MD, FRCPView Slideset
PCPedro CahnMD, PhDSlidesetHIVGlobal HIV Clinical Forum 2017Clinical Case -Reduced Drug Regimen- Pedro Cahn, MD, PhDView Slideset
PCPep CollMDSlidesetHIVGlobal HIV Clinical Forum 2017The Role of Integrase Inhibitors during HIV prevention- Pep Coll, MDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Clinical case of transmitted resistance to HIV Integrase Inhibitors- Dr. Carmen María González DomenechView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Mutations to Integrase inhibitors in real life- Dr. Isabel Viciana RamosView Slideset
SWSharon WalmsleyCM, MD, FRCPCSlidesetHIVGlobal HIV Clinical Forum 2017Optimal Use of Integrase Inhibitors in Women- Sharon Walmsley, FRCPC, MD, MSCView Slideset
MCMark CottonMD, PhDSlidesetHIVGlobal HIV Clinical Forum 2017Pediatric use of Integrase Inhibitors- Mark Cotton, MD, PhDView Slideset
DBDavid BackPhDSlidesetHIVGlobal HIV Clinical Forum 2017Clinical Pharmacology related considerations- David Back, PhDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Resistance Characteristics of Integrase Inhibitors- Charlotte Charpentier, PharmD, PhDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Potential role of Integrase Inhibitors in resource-limited settings- Gary Maartens, MDView Slideset
SlidesetHIVGlobal HIV Clinical Forum 2017Basic Science of Integrase Inhibitors - Recent Advances- Francois Clavel, MDView Slideset
